期刊文献+

沙利度胺联合化疗治疗难治性多发性骨髓瘤临床观察 被引量:3

下载PDF
导出
摘要 目的 观察沙利度胺联合化疗治疗难治性多发性骨髓瘤的疗效及其副作用。方法 沙利度胺起始剂量为200mg/d,以后每周以100mg递增,直至400~600mg/d。同时选用HD-Dex、VTD或VMD方案2~6疗程进行化疗。根据血清M蛋白和骨髓中骨髓瘤细胞的减少判断疗效。结果 8例难治性多发性骨髓瘤4例获部分缓解,2例进步,2例无效。无不能耐受的毒副作用。结论 沙利度胺联合化疗可作为难活性多发性骨髓瘤有效的治疗方法。
出处 《中国医药》 2006年第4期209-211,共3页 China Medicine
  • 相关文献

参考文献8

  • 1Barlogie B;Desikan R;Eddlemon P.Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide:identification of prognostic factors in a phase 2 study of 169patients[J],2001(02).
  • 2Barlogie B;Zangari M;Spencer T.Thalidomide in the management of multiple myeloma[J],2001(03).
  • 3Singhal S;Mehta J;Desikan R.Anti-tumor activity of thalidomide in refractory multiple myeloma[J],1999(21).
  • 4张卫平,郑翠苹,王肖岚,徐杰.反应停联合M_2方案治疗难治性复发性骨髓瘤18例疗效分析[J].肿瘤研究与临床,2004,16(3):179-179. 被引量:4
  • 5贺建霞,杨斌,张丽.沙利度胺联合化疗治疗难治性多发性骨髓瘤[J].白血病.淋巴瘤,2004,13(6):351-352. 被引量:3
  • 6Kropff MH;Lang N;Bisping G.Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide in primary refractory or relapsed multiple myeloma[J],2003(04).
  • 7Hideshima T;Chauhan D;Shima Y.Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy,2000(09).
  • 8Davies FE;Raje N;Hideshima T.Thalidomide and immunomodu latory derivatives augment natural killer cell cytotoxicity in multiple myeloma[J],2001(01).

二级参考文献8

  • 1Rajkumar S V, Witzig T E. A review of angiogenesis and antiangiogenie therapy with thalidomide in multiple myeloma [J].Cancer Treat Rev,2000,26:351 - 362.
  • 2Rajkumar S V, Leong T, Roche P C, et al.Prognostic value of bone marrow angiogensis in multiple myeloma[J]. Clin Cancer Rev,2000,6:3111-3116.
  • 3Singhal S, Mehta J, Eddlemon P ,et al.Marked anti-tumoreffect from anti-angiogenesis therapy with thalidomidein high risk refractory multiple myeIoma[J]. Blood,1998.98:318-322.
  • 4Hales B. Thalidomide on the comeback trail [J]. Nat Med, 1999, 5:489.
  • 5Singhal S, Mehtu J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma[J]. N Engl J Med, 1999,341(21):1565.
  • 6Raje N R, Anderson K. Thalidomide a revival story [J]. N Engl J Med, 1999, 341:1606.
  • 7Teosk, Sabourin P J, O'Brien K, et al.Metabolism of thalidomide in human microsomes.cloned human cytochrome p-450isozymes.and Hansen' disease patients[J]. J Biochem Mol Toxicol, 2000, 14(3):140-147.
  • 8张之南.血液病诊断及疗效标准[M].北京:科学出版社,1997.373.

共引文献13

同被引文献21

  • 1王敬君,付静.三氧化二砷联合沙利度胺治疗复发性难治性多发性骨髓瘤8例[J].中国基层医药,2006,13(2):330-331. 被引量:4
  • 2朱娟,吕晓毅.沙利度胺联合三氧化二砷治疗难治性多发性骨髓瘤疗效观察[J].中国医药,2006,1(4):204-205. 被引量:5
  • 3侯芸华,宋振岚,张永利,刘璟瑶.沙利度胺治疗急性白血病的部分机制研究[J].中国医药,2006,1(4):206-208. 被引量:7
  • 4张之南.血液病诊断与疗效标准.2版.北京:科学技术出版社,1998:258-263.
  • 5Kochenderfer JN, Kobayashl S, Wieder ED, et al. Loss of T-lymphocyle cional dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood, 2002, 100 (10): 3639-3645.
  • 6Stifter G, Heiss S, Castl G, el: al. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies with myelodysplastic syndromes: relationship to aneraia and prognosis. Eur J Haematol, 2005,75(6) :485-491.
  • 7Ma X,Does M,Raza,et al.A Myelodysplastic syndromes:incidence and survival in the United States.Cancer,2007,109 (8):1536-1542.
  • 8张之南,沈第.血液病诊断及疗效标准[M].2版.北京:科学出版社,1999:279-284
  • 9Hussein MA, Saleh M, Ravand F, et al. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma[ J]. Br J Haematol,2004,125 (6) :470-476.
  • 10Anderson KC, Boise LH, Louie R, et al. Arsenic trioxide in multiple myeloma: raft onale and future directions [ J ]. Cancer J,2002,8 (4) : 12-25.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部